☆ 4.7 Article

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

LANCET INFECTIOUS DISEASES (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, General & Internal

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial

Robert L. Gottlieb et al.

Summary: The study showed that treatment with bamlanivimab and etesevimab was significantly associated with a reduction in SARS-CoV-2 viral load at day 11 in nonhospitalized patients with mild to moderate COVID-19, compared to placebo. However, bamlanivimab monotherapy did not show a significant reduction in viral load. Ongoing clinical trials will focus on assessing the clinical benefits of antispike neutralizing antibodies in COVID-19 patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

A. C. Kalil et al.

Summary: Combination treatment with baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

Summary: In a platform trial involving patients hospitalized with Covid-19, among 314 patients who were also being treated with remdesivir, those who received the monoclonal antibody LY-CoV555 did not have better pulmonary function at day 5 than those who received placebo. The trial was stopped for futility.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Anil Gupta et al.

Summary: In this study, among nonhospitalized patients with symptomatic Covid-19, sotrovimab treatment significantly reduced the risk of disease progression leading to hospitalization or death compared to placebo. Patients receiving sotrovimab also had a lower rate of serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Accurate point-of-care serology tests for COVID-19

Charles F. Schuler et al.

Summary: The study conducted COVID-19 antibody testing in high-risk populations at the point of care, finding that finger-stick blood antibody testing was significantly effective in identifying antibodies from prior infections. Using serum did not improve the sensitivity or specificity of the testing, and almost all individuals with COVID-19 infection produced detectable antibodies to the virus.

PLOS ONE (2021)

添加到收藏夹

Article Medicine, General & Internal

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

M. Dougan et al.

Summary: In this phase 3 trial, the combination of bamlanivimab plus etesevimab was found to reduce the incidence of Covid-19-related hospitalization and death among high-risk ambulatory patients compared to placebo, and also accelerated the decline in SARS-CoV-2 viral load.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Bin Ju et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Cross-neutralization ofSARS-CoV-2 by a human monoclonal SARS-CoV antibody

Dora Pinto et al.

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Infectious Diseases

A minimal common outcome measure set for COVID-19 clinical research

J. C. Marshall et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A perspective on potential antibody-dependent enhancement of SARS-CoV-2

Ann M. Arvin et al.

NATURE (2020)

添加到收藏夹

Review Microbiology

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Wen Shi Lee et al.

NATURE MICROBIOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19 A Randomized Clinical Trial

Wesley H. Self et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Review Medicine, Research & Experimental

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

Marco Tuccori et al.

MABS (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides

Amita Datta-Mannan

DRUG METABOLISM AND DISPOSITION (2019)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.